《公司業績》ASM太平洋(00522.HK)首三季純利6.2億元升54%
ASM太平洋(00522.HK)公布截至今年9月底止首三季業績,營業額119.69億元,按年升4.7%。純利6.21億元,按年升54.2%;每股盈利1.52元。
單計第三季,ASM太平洋收入為42.7億元按年增2.6%,集團收入接近預測的上限;純利2.32億元,按年升3.82%。季內新增訂單總額為45.2億元,按年增12.4%,按季增23.5%,毛利率為 32.9%,按年減少1.82個百分點。
公司表示,在設備市場氣氛改善的情況下,集團預計今年第四季度的收入將介乎於5.3億美元至5.9億美元之間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.